95 related articles for article (PubMed ID: 7923099)
1. Immunotherapy in liver tumours: I. Combined administration of recombinant interleukin-2 (IL-2) and interferon-alpha through the subcutaneous transposed spleen prolongs the half-life of IL-2 in vivo and enhances antitumor effects.
Liu DL; Seifert J; Cwikiel W
Cancer Lett; 1994 Sep; 85(1):31-7. PubMed ID: 7923099
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis.
Liu DL; Håkansson CH; Seifert J
Cancer Lett; 1994 Sep; 85(1):39-46. PubMed ID: 7923100
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in liver tumors: III. A new experimental model of metastatic liver tumors from colorectal carcinoma for cytokine therapy.
Liu DL; Radnell M; Svanberg K; Seifert J
Cancer Lett; 1995 Jan; 88(2):211-19. PubMed ID: 7874695
[TBL] [Abstract][Full Text] [Related]
4. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
[TBL] [Abstract][Full Text] [Related]
6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
7. Experimental liver cancer: improved response after hepatic artery ligation and infusion of tumor necrosis factor-alpha and interferon-gamma.
Yang R; Liu Q; Rescorla FJ; Grosfeld JL
Surgery; 1995 Oct; 118(4):768-72; discussion 772-4. PubMed ID: 7570335
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of IL-2 entrapped in liposomes on rat hepatoma, AH-66].
Konno H; Toriyama H; Aoki K; Baba S; Sakaguchi S; Yamashita A; Tadakuma T
Gan To Kagaku Ryoho; 1989 Jan; 16(1):53-8. PubMed ID: 2783545
[TBL] [Abstract][Full Text] [Related]
9. [Induction of endogenous antitumor activities in the portal vein by using a subcutaneously-imbedded pediculated spleen in the rat; experimental study of adjuvant immunotherapy in liver metastases].
Fujii M
Nihon Geka Gakkai Zasshi; 1988 Nov; 89(11):1850-9. PubMed ID: 2462667
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
12. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
13. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
14. The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2.
Kirchner H; Körfer A; Evers P; Szamel MM; Knüver-Hopf J; Mohr H; Franks CR; Pohl U; Resch K; Hadam M
Cancer; 1991 Apr; 67(7):1862-4. PubMed ID: 2004299
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
16. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hepatocellular carcinoma by transfecting interleukin-12 and interleukin-2 fusion gene intrasplenically, an experimental study].
Yang JH; Fan RF; Qian QJ; You TG; Xue HB; Su CQ; Cao HF; Wu MC
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):740-3. PubMed ID: 12899748
[TBL] [Abstract][Full Text] [Related]
18. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.
Arroyo PJ; Bash JA; Wallack MK
Cancer Immunol Immunother; 1990; 31(5):305-11. PubMed ID: 2376048
[TBL] [Abstract][Full Text] [Related]
19. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
Lygidakis NJ; Kosmidis P; Ziras N; Parissis J; Kyparidou E
J Interferon Cytokine Res; 1995 May; 15(5):467-72. PubMed ID: 7544232
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
